We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Korro Bio, Inc. is next on our list of best biotech stocks. TheFly reported on January 29 that H.C. Wainwright upgraded KRRO from Neutral to Buy with a $20 price target. The firm highlighted KRRO-121 as a second, independently risk-mitigated asset and described it as a “call option” that is separate from the company’s earlier KRRO-110 program. H.C. Wainwright highlighted the independent potential of KRRO-121 by pointing out th ...

Korro Bio, Inc. (KRRO) shares soared 13.9% in the last trading session to close at $13.31. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 45.9% gain over the past four weeks.Korro Bio’s stock price gain can be attributed to increasing investor confidence in Korro’s pipeline diversification, particularly the emergence of KRRO-121 as a meaningful second asset, the first being KRRO-110, an RNA-editing therapeutic candidate using th ...

PresentationOperator Greetings. Welcome to Korro Bio's Analyst Day discussing KRRO-121, a potential first-in-class treatment for ammonia control. [Operator Instructions] Please note, this conference is being recorded. This Analyst Day presentation will include forward-looking statements. Actual results could differ materially from these forward-looking statements. Please see Slide 2 of the accompanying presentation and our most recent annual and quarterly reports filed with the SEC for important risk factor ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: Barclays upgraded Zillow Group (ZG) to Equal Weight from Underweight with a price target of $72, up from $66. The firm believes a lot of downside risks are priced into shares. Rosenblatt upgraded Fortinet (FTNT) to Buy from Neutral with a price target of $100, up from $85, ahead of the Q4 report on February 5. ...

At 8:15 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading hig ...

Korro Bio (NasdaqCM:KRRO) 2026 Analyst Day January 27, 2026 08:00 AM ET Company ParticipantsBruce Scharschmidt - Independent DirectorLoïc Vincent - Chief Scientific OfficerMichelle Dinneen - Social WorkerRam Aiyar - CEO and PresidentTodd Chappell - COOConference Call ParticipantsCatherine Novack - Research AnalystKeay Nakae - MD and Senior Research AnalystKostas Biliouris - MD and Senior AnalystMitchell Kapoor - VP and Senior Biotechnology AnalystMyles Minter - Partner and Biotech Equity Research AnalystRya ...

January 27th, 2026 Analyst Day 2026 KRRO-121: A Potential First-in-Class Treatment for Ammonia Control 1 Forward-Looking Statements and Disclaimers Forward-Looking Statements Certain statements in this presentation may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, but are not limited to, express or implied statements regarding expectations, hopes, beliefs, intentions or strategies of Korro B ...

Company Overview - Korro Bio aims to develop transformative medicines targeting both rare and highly prevalent indications by activating biological pathways [3] - The company utilizes a chemically modified oligonucleotide or RNA to effect changes in protein structure through RNA editing, specifically changing adenosine to inosine without altering DNA [3] Presentation Context - The presentation was introduced by Henry Jiang from JPMorgan, highlighting the significance of the event and the presence of Korro Bio's leadership [1][2] - Ram Aiyar, the President and CEO of Korro Bio, expressed gratitude for the opportunity to present and emphasized the company's mission [2]

- Program to feature presentations from the company management about KRRO-121 for the potential treatment of hyperammonemia, a leading clinical hepatologist about ammonia-driven diseases, and a caregiver sharing perspectives on living with urea cycle disorder - CAMBRIDGE, Mass., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that the company will host a virtual Analyst Day on Tuesday, January 27, 2026, from 8 a.m. – 10 a.m. ET, with members of the Korro management t ...

Summary of Korro Bio Conference Call Company Overview - **Company**: Korro Bio - **Industry**: Biotechnology, specifically focusing on RNA editing technologies for therapeutic applications Core Points and Arguments 1. **Vision and Technology**: Korro Bio aims to develop transformative medicines for both rare and prevalent conditions by activating biological pathways through RNA editing, which allows for precise modifications without altering DNA [2][4] 2. **RNA Editing Modality**: The company utilizes chemically modified oligonucleotides to edit RNA, enabling single base changes that can impact protein structure and function, offering a transient solution rather than permanent genetic modifications [3][10] 3. **Pipeline Focus**: The lead program, Korro 121, is set to enter clinical trials in the latter half of the year, targeting ammonia reduction in patients with liver conditions [4][11] 4. **Clinical Development**: Korro Bio plans to provide insights into their clinical approach and patient needs during an upcoming educational session on January 27 [5] 5. **Korro 110 Termination**: The company has decided to terminate the Korro 110 program due to unsatisfactory clinical data and structural integrity issues observed in patient trials [12][20] 6. **Market Potential**: Korro Bio identifies significant unmet medical needs in conditions associated with elevated ammonia levels, with a patient population of approximately 4,500 in the U.S. and a similar number in Europe [16][17] 7. **Regulatory Filing**: Anticipation of a regulatory filing for Korro 121 in the second half of the year, with expectations for rapid clinical data generation [11][18] 8. **Safety Profile**: RNA editing is posited to have a high specificity and low likelihood of off-target effects compared to DNA editing, enhancing the safety profile of Korro's therapies [30][31] Additional Important Content 1. **Biological Pathways**: The technology allows for modulation of proteins to activate biological pathways, which has not been achievable with traditional gene therapies [10][28] 2. **Next-Generation Programs**: Korro Bio is advancing towards a next-generation Alpha-1 product that shows promise for achieving over 90% editing in vivo, significantly improving upon previous attempts [22][23] 3. **Unique Therapeutic Approach**: The company emphasizes the transient nature of their therapies, which is particularly beneficial for chronic conditions where permanent changes could lead to complications [36] 4. **Dosing Frequency**: Korro Bio's therapies are designed for infrequent dosing, potentially once a month, which contrasts with the more frequent dosing required by traditional therapies [15][36] 5. **Research and Development**: The company is leveraging machine learning to enhance target identification and therapy design, indicating a forward-thinking approach to drug development [8][30] This summary encapsulates the key points discussed during the conference call, highlighting Korro Bio's innovative approach to RNA editing and its implications for future therapeutic developments.